Small Cell Lung Cancer Patient with Anti-transcriptional Intermediary Factor 1γ Antibody Who Developed Dermatomyositis after Successful Chemoradiotherapy

Takafumi Aritomi; Takashi Kido; Kazuhisa Nakano; Yurie Satoh; Shingo Noguchi; Takanobu Jotatsu; Tetsuya Hanaka; Minoru Satoh; Yoshiya Tanaka; Kazuhiro Yatera

doi:10.2169/internalmedicine.1007-18

CASE REPORTS

Small Cell Lung Cancer Patient with Anti-transcriptional Intermediary Factor 1γ Antibody Who Developed Dermatomyositis after Successful Chemoradiotherapy

Takafumi Aritomi, Takashi Kido, Kazuhisa Nakano, Yurie Satoh, Shingo Noguchi, Takanobu Jotatsu, Tetsuya Hanaka, Minoru Satoh, Yoshiya Tanaka, Kazuhiro Yatera

Author information

Takafumi Aritomi
First Department of Internal Medicine, University of Occupational and Environmental Health, Japan
Takashi Kido
Department of Respiratory Medicine, University of Occupational and Environmental Health, Japan
Kazuhisa Nakano
First Department of Internal Medicine, University of Occupational and Environmental Health, Japan
Yurie Satoh
First Department of Internal Medicine, University of Occupational and Environmental Health, Japan
Shingo Noguchi
Department of Respiratory Medicine, University of Occupational and Environmental Health, Japan
Takanobu Jotatsu
Department of Respiratory Medicine, University of Occupational and Environmental Health, Japan
Tetsuya Hanaka
Department of Respiratory Medicine, University of Occupational and Environmental Health, Japan
Minoru Satoh
Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, Japan
Yoshiya Tanaka
First Department of Internal Medicine, University of Occupational and Environmental Health, Japan
Kazuhiro Yatera
Department of Respiratory Medicine, University of Occupational and Environmental Health, Japan

Keywords: anti-transcriptional intermediary factor 1 γ antibody, chemoradiotherapy, dermatomyositis, autoantibody, small-cell lung cancer

JOURNAL OPEN ACCESS

2019 Volume 58 Issue 3 Pages 427-431

DOI https://doi.org/10.2169/internalmedicine.1007-18

Browse “Advance online publication” version

Details

Abstract

We herein report a 63-year-old woman with small-cell lung cancer (SCLC) who developed dermatomyositis (DM) after initial chemoradiotherapy despite tumor reduction. Serum anti-transcriptional in termediary factor (TIF) 1γ antibody was detected before the development of DM, and its levels increased over time. She died five months after the diagnosis of SCLC. Anti-TIF1γ antibody is known to be a marker for cancer-associated DM (CAM); however, the present case indicates that the antibody can be found in cancer patients without DM. This case is also unusual, as DM developed later despite successful chemoradiotherapy.

Corresponding author